-
AstraZeneca launches next-generation PARP inhibitors to continue Lynparza's success
Time of Update: 2021-04-18
AstraZeneca hopes that AZD5305 will be a successful follow-up product to Lynparza and provide a wider range of combination treatment options and earlier treatments because of its higher specificity and the potential to reduce safety risks.
-
my country’s first case of “serious” dishonesty related drugs was suspended for online trading
Time of Update: 2021-04-18
cn/news/yyzb/" target="_blank"> procurement procurement In August 2020, the National Medical Insurance Administration launched the construction of a medical price and credit evaluation system, and gave rebates and other outstanding issues in the medical field to give play to the guiding and standardizing role of the centralized procurement market for medical products, and promote the return of reasonable prices of medical products.
-
Renfu Pharmaceutical Memantine Hydrochloride Sustained-Release Capsules Received U.S. FDA Approval Number
Time of Update: 2021-04-18
On April 7, Renfu Medicine issued an announcement stating that its holding subsidiary, Yichang Renfu, had recently received an approval number from the US FDA for memantine hydrochloride sustained-release capsules.
According to statistics from IQVIA, the total sales of the drug in the US market in 2020 will be approximately 61 million U.
-
Break out on weekends!
Time of Update: 2021-04-18
On the afternoon of April 11, the official website of the State Supervision Commission of the Central Commission for Discipline Inspection issued a notice: Dai Longyong, the legal representative of Jiangxi Yongchang Pharmaceutical Co.
The official WeChat account of Jiangxi Provincial Commission for Discipline Inspection and Supervision, "Incorruption Jiangxi" also released the news today.
-
Official support!
Time of Update: 2021-04-18
Online prescription drugs welcome breakthrough Hainan established the country's first independent construction and operation electronic prescription center The "Special Measures" proposes to support the development of Internet prescription drug sales.
-
Kelun Class 1 new drug hits 2 billion injections, the first four major products that have been reviewed and will be approved
Time of Update: 2021-04-18
The clinical application of KL590586 Capsules, a new class 1 drug, has been accepted by CDE, Moxifloxacin Hydrochloride Eye Drops, Propofol Fumarate, Tenofo The registration status of four generic drugs including Wei tablets, ticagrelor tablets and ropivacaine hydrochloride injection has been changed to "under approval" and is expected to be approved in the near future.
-
Hainan Free Trade Port relaxes drug market access to prescription drug online sales policy
Time of Update: 2021-04-18
(Leading units: National Health Commission, National Food and Drug Administration, National Development and Reform Commission are responsible according to the division of responsibilities; Participating units: National Medical Insurance Bureau, China Banking Regulatory Commission, State Administration of Traditional Chinese Medicine) (2) Support the innovative development of Hainan's localized high-end medical equipment.
-
The 6.5 billion market welcomes the impact: Howson, Better, Dongyang...
Time of Update: 2021-04-18
414 ，、“”，。，4，，？，1，？，。 20，1 1：2020 ： ，2020，20%，，，9%，65。，，，？ 1：2021（） ：MED2. 0 Since 2021, a total of 20 new antithrombotic drugs (according to product name + company statistics) have been approve
-
Huahai Pharmaceutical: Q1 deduction of non-net profit pre-cut by 15%-25%, unable to judge the impact of the valsartan incident
Time of Update: 2021-04-18
At the same time, in the first quarter of 2021, the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses has declined, mainly due to changes in the sales structure of API products, the continued impact of the FDA ban on the preparations business in the United States, and the company's continuous increase in R&D investment.
-
Kanghong Pharmaceutical Stops Global Multicenter Clinical Trial of Conbercept Ophthalmic Injection
Time of Update: 2021-04-18
On the evening of April 9th, Kanghong Pharmaceutical issued an announcement stating that the global multi-center clinical trial of Conbercept ophthalmic injection was stopped, which means that its core product, Conbercept, which has been highly anticipated by the market, failed to "go out to sea".
-
Yuandong Biology is showing its power!
Time of Update: 2021-04-18
com, in 2019, the sales of Dabigatran Etexilate Capsules in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan, a year-on-year increase of 39.
-
The start of the second batch of consumables collection in Fujian involves 7 categories such as pacemakers and coronary balloons
Time of Update: 2021-04-18
Enterprise proposed to be selected ① 1 set of hemorrhoid stapler (the total purchase quantity of the same enterprise accounts for ≥5% ) The first round: Except for the one company with the lowest weighted quotation in this group, the two companies that ranked the bottom two in decline are eliminated, and the remaining companies enter the second round.
-
China National Institute of Biological Sciences of Sinopharm Group's recombinant new coronavirus vaccine approved for clinical trials
Time of Update: 2021-04-18
China Biotech stated that the genetic recombinant protein vaccine has a mature technology route and is suitable for large-scale production.
-
57 large varieties, the results of collective procurement announced (list attached)
Time of Update: 2021-04-18
Medical Network News on April 12 The results of 57 large varieties to be selected are announced On April 8, the Joint Procurement Office of Guangxi Pharmaceutical Group issued the "Announcement on the Proposed Selection Results of the Sixth Batch of Guangxi Pharmaceutical Group Procurement (Second Batch)" and announced the proposed selection of 57 product regulations and hundreds of companies.
-
Yiling Pharmaceutical's Aniprofen Injection Formally Started Phase III Clinical Trial
Time of Update: 2021-04-18
On April 13, Yiling Pharmaceutical issued an announcement that the company's Phase III clinical trial plan for the company's 1.
From April 2019 to June 2020, the Phase II clinical trial was completed in 8 centers including the Third Xiangya Hospital of Central South University.
-
Frequent adverse reactions after entering AstraZeneca, Johnson & Johnson vaccine is also thrombosis?
Time of Update: 2021-04-18
It is understood that the European Medicines Agency (EMA) issued an announcement on the 9th that 4 cases of abnormal thrombosis accompanied by thrombocytopenia were found among the vaccinators of Johnson & Johnson vaccine, and 1 of them died as a result.
-
Special rectification of drug online sales is coming!
Time of Update: 2021-04-18
According to the arrangements, Shanxi will focus on safety net sales of the drug quality and safety, according to the characteristics of Internet sales of drugs, for key areas, focusing on business , never obtaining the qualification to carry out the problem of drugs Internet sales, drug sales net sellers of illegal drugs through a network problem , Three dimensions, including the performance of third-party platforms for online transaction services, continued to carry out special rectifications in depth.
-
Behind Ali's 18.2 billion huge fine, pharmaceutical anti-monopoly forces the entire industry to comply with regulations!
Time of Update: 2021-04-18
877 million yuan and 152,600 yuan respectively by the National Development and Reform Commission for illegally controlling the raw material of promethazine hydrochloride and driving up prices, causing related pharmaceutical companies to suspend production This is also the first fine issued by China for the monopoly of APIs.
-
Subcutaneous RNAi therapy ALN-AGT Phase 1 clinical trial results are positive
Time of Update: 2021-04-18
Retrieved April 11, 2021, from /20210411005027/en[2] Safety, Pharmacodynamics, and Blood Pressure Effects of ALN-AGT, an RNA Interference Therapeutic Targeting Angiotensinogen, in a Randomized Single Ascending Dose Study of Hypertensive Adults.
Retrieved April 11, 2021, from /wp-content/uploads/2021/04/Safety-Pharmacodynamics-and-Blood-Pressure-Effects-of-ALN-AGT-an-RNA-Interference-Therapeutic-Targeting-Angiotensinogen-in-a-Randomized-Single-Ascending -Dose-Study-of-Hypertensive-Adults.
-
The salary of the CEO of the new crown vaccine manufacturer has soared!
Time of Update: 2021-04-18
The foreign media BioSpace website pays attention to the annual salary of vaccine developer CEO:Pfizer: Albert BourlaPfizer: Albert BourlaPfizer CEO Bora will make a net profit of US$21 million in 2020 because his company has cooperated with German BioNTech and became the first company to obtain emergency use authorization for the COVID-19 vaccine in the United States.
